Göran Ando has over 30 years’ experience in the pharmaceutical industry. He began his career in 1978 as Medical Director of Pfizer AB and continued as head of clinical research with Pfizer International in the USA. Dr. Ando then became VP, Medical and Scientific Affairs at Bristol-Myers and also returned to Sweden as Chairman of the Astra Research Center. Between 1989 and 1995, he held a number of senior positions at Glaxo, including head of research and development for Glaxo Group Research. Dr. Ando joined Pharmacia AB in 1995 as Executive Vice President and Deputy CEO and moved to the United States in 1997 to lead research and development with additional responsibilities for manufacturing, information technology, business development and mergers and acquisitions. During his eight-year tenure as head of research and development at Pharmacia / Pharmacia & Upjohn, 17 new drugs were approved by the FDA, prior to Pfizer’s acquisition of Pharmacia.
Dr. Ando was then named CEO of Celltech Group PLC in the UK, one of the most successful European biotechnology companies, until it was acquired by UCB Pharma in 2005.
Göran Ando was elected in 2005 as a board member of Novo Nordisk A / S, where he became Vice Chairman in 2006 and Chairman between 2013 and 2018.
Göran Ando is Chairman of the Board of Eyepoint Pharmaceuticals (USA) and Tessa Therapeutics (Singapore) and a board member of EUSA Pharma (UK) and Selecta Biosciences (USA).
Bengt Gustavsson has many years’ experience from the pharmaceutical industry in Sweden and the Nordic countries, and has been Nordic Medical Director at Novartis Oncology, Nordic Clinical Research Director at Sanofi-Aventis, Nordic Medical Head of Celgene and Global Head of Medical Affairs på Oncopeptides. Bengt Gustavsson is a former reserve officer in the Swedish Air Force
Medical Director at Nanexa since 2021. Owner and CEO of Sangus Jazz AB, Sr Global Medical Affairs Director at Oncopeptides AB.
Mårten Rooth is a co-founder of Nanexa. He has extensive experience in Atomic Layer Deposition (ALD), with several published scientific articles in the field.
Employed by Nanexa since 2008 as researcher and development manager. Deputy Board Member of Velotek Sweden AB.
Urban Paulsson has worked for more than 25 years in the pharmaceutical industry with various legal issues in a variety of roles, e.g. as General Counsel and Vice President Corporate Development at Camurus AB and General Counsel at Vitrolife AB. He has previously worked as a lawyer and Partner at the law firms Bird & Bird and Nordia.
In recent years, Urban has founded four biotechnology companies – Cinclus Pharma, Gesynta Pharma, Cormorant Pharmaceuticals and Buzzard Pharmaceuticals.
Cormorant was successfully sold to BMS 2016.
Chairman of the Board of Evident Life AB, Gesynta Pharma AB, Buzzard Pharmaceuticals AB, MetaCurUm Biotech AB, Cavis Technologies AB, Brf Bellman AB, Cordivest AB and board members of Nylof Holding AB and Urban Paulsson AB. Urban is active as an investor in life science.
Otto Skolling has worked for more than 25 years in the pharmaceutical industry, primarily in business development and financing, but also product development. Among other roles, Otto has worked at PharmaciaUpJohn (Project Director), Novozymes (Director Product Pipeline, Business Development & Director M&S Biopharmaceutical ingredients), Karolinska Development (Vice President Business Development / Portfolio Management). Otto also has extensive experience from board work from start-up companies in the pharmaceutical industry
Responsible for Business Development at Nanexa since 2015, Chief Business Officer at Asarina Pharma AB, Board member in Athera Biotechnologies AB, Lipidor AB and Bactaviva AB, CEO and Board member in Isles of Wines AB and CEO and chairman of Pharmor AB.